IL158155A0 - Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo - Google Patents

Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo

Info

Publication number
IL158155A0
IL158155A0 IL15815502A IL15815502A IL158155A0 IL 158155 A0 IL158155 A0 IL 158155A0 IL 15815502 A IL15815502 A IL 15815502A IL 15815502 A IL15815502 A IL 15815502A IL 158155 A0 IL158155 A0 IL 158155A0
Authority
IL
Israel
Prior art keywords
erythropoietin
vivo
induced toxicity
cytotoxic agent
ameliorate
Prior art date
Application number
IL15815502A
Other languages
English (en)
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158155(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of IL158155A0 publication Critical patent/IL158155A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL15815502A 2001-04-09 2002-04-08 Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo IL158155A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28262101P 2001-04-09 2001-04-09
PCT/US2002/011081 WO2002080676A1 (en) 2001-04-09 2002-04-08 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Publications (1)

Publication Number Publication Date
IL158155A0 true IL158155A0 (en) 2004-03-28

Family

ID=23082337

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15815502A IL158155A0 (en) 2001-04-09 2002-04-08 Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo
IL158155A IL158155A (en) 2001-04-09 2003-09-29 Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
IL198783A IL198783A0 (en) 2001-04-09 2009-05-17 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL158155A IL158155A (en) 2001-04-09 2003-09-29 Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
IL198783A IL198783A0 (en) 2001-04-09 2009-05-17 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Country Status (22)

Country Link
US (2) US20020169128A1 (xx)
EP (1) EP1377164B1 (xx)
JP (1) JP4428924B2 (xx)
KR (1) KR100885525B1 (xx)
CN (2) CN101152565A (xx)
AT (1) ATE399020T1 (xx)
AU (1) AU2002256133B2 (xx)
BR (1) BR0208727A (xx)
CA (1) CA2443025A1 (xx)
DE (1) DE60227244D1 (xx)
DK (1) DK1377164T3 (xx)
ES (1) ES2309166T3 (xx)
HU (1) HUP0303838A3 (xx)
IL (3) IL158155A0 (xx)
MX (1) MXPA03009182A (xx)
NO (1) NO20034504L (xx)
NZ (1) NZ528675A (xx)
PL (1) PL373361A1 (xx)
PT (1) PT1377164E (xx)
RU (1) RU2296563C2 (xx)
WO (1) WO2002080676A1 (xx)
ZA (1) ZA200307803B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1628686A2 (en) 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
RS51130B (sr) * 2003-05-12 2010-10-31 Affymax Inc. Novi peptidi koji se vezuju za eritropoietinski receptor
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
EP2336162A1 (en) * 2003-05-12 2011-06-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2008023725A1 (fr) * 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Agent préventif et/ou thérapeutique pour une neuropathie périphérique
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
EP1992355A1 (en) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
EP4026563A1 (en) * 2015-06-18 2022-07-13 Yeda Research and Development Co. Ltd Conditioning protocols and use of same for tissue regeneration
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859765A (en) * 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) * 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) * 1987-01-22 1988-12-30 Erga Srl Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4856871A (en) * 1987-08-31 1989-08-15 General Electric Company Replaceable laser and lens assembly
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
BR0010316A (pt) * 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs

Also Published As

Publication number Publication date
RU2003132584A (ru) 2005-04-10
RU2296563C2 (ru) 2007-04-10
WO2002080676A1 (en) 2002-10-17
JP4428924B2 (ja) 2010-03-10
DK1377164T3 (da) 2008-10-13
BR0208727A (pt) 2005-05-10
EP1377164A4 (en) 2005-05-04
HUP0303838A3 (en) 2010-03-29
NO20034504L (no) 2003-12-09
KR100885525B1 (ko) 2009-02-26
PT1377164E (pt) 2008-09-30
HUP0303838A2 (hu) 2004-03-01
US20110195046A1 (en) 2011-08-11
CN101152565A (zh) 2008-04-02
JP2004532840A (ja) 2004-10-28
ATE399020T1 (de) 2008-07-15
ES2309166T3 (es) 2008-12-16
AU2002256133B2 (en) 2007-05-31
NO20034504D0 (no) 2003-10-08
EP1377164A1 (en) 2004-01-07
EP1377164B1 (en) 2008-06-25
IL198783A0 (en) 2010-02-17
DE60227244D1 (de) 2008-08-07
CN1499927A (zh) 2004-05-26
ZA200307803B (en) 2005-02-09
KR20030087064A (ko) 2003-11-12
IL158155A (en) 2009-12-24
US20020169128A1 (en) 2002-11-14
NZ528675A (en) 2006-10-27
PL373361A1 (en) 2005-08-22
CA2443025A1 (en) 2002-10-17
MXPA03009182A (es) 2004-02-17
CN100379446C (zh) 2008-04-09

Similar Documents

Publication Publication Date Title
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AP2002002703A0 (en) Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
SE0001899D0 (sv) New compounds
HK1085667A1 (en) Non-nucleoside reverse transcriptase inhibitors
TNSN06377A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
EP1676488A3 (en) Compositions and methods for body weight management
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
RS44204A (xx) Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita&#39; tireomimetica e relative formulazioni farmaceutiche.
RS44304A (xx) Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
EP1930023A3 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
PL367630A1 (en) Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
TW200500376A (en) Novel adenosine analogues and their use as pharmaceutical agents